Latest Period
Q1 2026
Security Snapshot
Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK (KNSA) Institutional Ownership
CUSIP: G52694109
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
225
Shares (Excl. Options)
45,402,644
Price
$48.15
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / CLASS A COMMON STOCK
- Symbol
- KNSA on Nasdaq
- Shares outstanding
- 45,862,839
- Price per share
- $43.05
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 45,402,644
- Total reported value
- $2,181,819,286
- % of total 13F portfolios
- 0%
- Share change
- +2,585,665
- Value change
- +$142,641,616
- Number of holders
- 225
- Price from insider filings
- $43.05
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- KNSA - Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK is tracked under CUSIP G52694109.
- 225 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 220 to 225 between Q4 2025 and Q1 2026.
- Reported value moved from $1,771,583,633 to $2,181,819,286.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 225 institutions filings for Q1 2026.
Security key
G52694109
Latest holder period
Q1 2026
13F holders
225
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
KNSA full holder history
Kiniksa Pharmaceuticals International, plc SEC filings
Kiniksa Pharmaceuticals International, plc company facts
Kiniksa Pharmaceuticals International, plc insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP G52694109:
Significant Owners of Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK (KNSA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 15% | +38% | $326,692,012 | +$93,051,943 | 6,787,700 | +40% | FMR LLC | 31 Mar 2026 |
| Rubric Capital Management LP | 7.4% | -21% | $139,836,713 | -$24,414,238 | 3,328,653 | -15% | Rubric Capital Management LP | 31 Dec 2025 |
| VANGUARD GROUP INC | 7% | $118,941,532 | 3,063,135 | The Vanguard Group | 30 Sep 2025 | |||
| TANG CAPITAL MANAGEMENT LLC | 5.2% | $46,556,874 | 2,178,609 | TANG CAPITAL MANAGEMENT, LLC | 28 Mar 2025 | |||
| BlackRock, Inc. | 1% | -88% | $11,570,238 | -$51,021,128 | 418,151 | -82% | BlackRock, Inc. | 30 Jun 2025 |
As of 31 Mar 2026, 225 institutional investors reported holding 45,402,644 shares of Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK (KNSA). This represents 99% of the company’s total 45,862,839 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK (KNSA) together control 71% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 6,823,700 | +315% | 0.02% | $328,561,167 |
| Rubric Capital Management LP | 8.2% | 3,750,000 | +13% | 2.2% | $180,562,500 |
| BAKER BROS. ADVISORS LP | 6.2% | 2,826,246 | 0% | 0.78% | $136,083,745 |
| TANG CAPITAL MANAGEMENT LLC | 4.9% | 2,259,889 | 0% | 5.5% | $108,813,655 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.9% | 1,766,268 | 0% | 0% | $85,045,804 |
| ACADIAN ASSET MANAGEMENT LLC | 2.9% | 1,336,313 | -22% | 0.09% | $64,319,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.9% | 1,333,093 | 0% | 0% | $64,188,428 |
| MORGAN STANLEY | 2.2% | 997,786 | -27% | 0% | $48,043,396 |
| D. E. Shaw & Co., Inc. | 2.1% | 959,257 | -23% | 0.04% | $46,188,225 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.9% | 892,666 | -16% | 0.02% | $42,981,868 |
| DIMENSIONAL FUND ADVISORS LP | 1.8% | 811,922 | +19% | 0.01% | $39,085,722 |
| Spruce Street Capital LP | 1.7% | 761,063 | +75% | 8.8% | $36,645,183 |
| BANK OF AMERICA CORP /DE/ | 1.6% | 735,940 | +221% | 0% | $35,435,511 |
| Qube Research & Technologies Ltd | 1.5% | 686,853 | -10% | 0.05% | $33,071,972 |
| Connor, Clark & Lunn Investment Management Ltd. | 1.4% | 649,629 | -12% | 0.07% | $31,279,636 |
| BNP PARIBAS FINANCIAL MARKETS | 1.4% | 647,731 | 0% | 0.02% | $31,188,248 |
| Point72 Asset Management, L.P. | 1.4% | 640,958 | -20% | 0.05% | $30,862,128 |
| SG Americas Securities, LLC | 1.4% | 640,179 | +18% | 0.03% | $30,825,000 |
| Pictet Asset Management Holding SA | 1.4% | 623,288 | -21% | 0.03% | $30,011,317 |
| Driehaus Capital Management LLC | 1.3% | 611,398 | -3.4% | 0.22% | $29,438,814 |
| RICE HALL JAMES & ASSOCIATES, LLC | 1.3% | 608,416 | +2% | 1.6% | $29,295,230 |
| ALLIANCEBERNSTEIN L.P. | 1.3% | 598,888 | +82% | 0.01% | $24,704,130 |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 564,420 | -32% | 0.02% | $27,176,823 |
| DEUTSCHE BANK AG\ | 1.1% | 523,691 | -17% | 0.01% | $25,215,722 |
| Soleus Capital Management, L.P. | 1.1% | 521,353 | -11% | 1% | $25,103,147 |
Institutional Holders of Kiniksa Pharmaceuticals International, plc - CLASS A COMMON STOCK (KNSA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 45,402,644 | $2,181,819,286 | +$142,641,616 | $48.15 | 225 |
| 2025 Q4 | 42,951,243 | $1,771,583,633 | +$79,894,135 | $41.25 | 220 |
| 2025 Q3 | 40,790,628 | $1,583,711,476 | +$42,923,169 | $38.83 | 200 |
| 2025 Q2 | 39,765,765 | $1,100,293,484 | +$3,474,538 | $27.67 | 186 |
| 2025 Q1 | 39,936,950 | $887,052,494 | +$25,344,007 | $22.21 | 173 |
| 2024 Q4 | 38,910,834 | $769,756,202 | -$20,642,445 | $19.78 | 156 |
| 2024 Q3 | 39,503,444 | $987,347,556 | +$124,891,730 | $24.99 | 172 |
| 2024 Q2 | 35,248,812 | $658,014,093 | +$655,780,340 | $18.67 | 126 |